Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
BCR-ABL/c-ABL
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "BCR-ABL/c-ABL" in MCE Product Catalog:
3
Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .
3
3 Cited Publications
Synonyms: HHGV678 mesylate
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model .
PROTAC BCR-ABL Degrader-1 is a PROTAC degrader targeting BCR-ABL, and also selectively inhibits cancer cell proliferation. PROTAC BCR-ABL Degrader-1 induces degradation via the ubiquitin-proteasome system to reduce protein levels. PROTAC BCR-ABL Degrader-1 can be used for research on chronic myeloid leukemia .
Cat. No.: HY-153582
ML 2-23 is a PROTAC degrader that recruits RNF114 to target BCR-ABL/c-ABL for degradation. ML 2-23 promotes proteasome-dependent degradation of the target protein and inhibits phosphorylation of downstream CRKL. At concentrations used for BCR-ABL degradation, ML 2-23 only causes slight impairment to the viability of cancer cells. ML 2-23 can be used in the research of chronic myeloid leukemia .
Cat. No.: HY-160478
CAS No.: 839708-29-1
GNF-6 (Compound 14) inhibits the gatekeeper threonine residue mutation of BCR-ABL-T315I with IC50s of 0.25 μM, 0.09 μM and 0.590 μM for c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants, respectively. GNF-6, an ATP competitive inhibitor, disrupts the assembly of the hydrophobic spine (a network of hydrophobic interactions), thereby locking the kinase in an inactive ‘DFG-out’ conformation .
Cat. No.: HY-P71685
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Cat. No.: HY-P77308
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Species:
Source:
Cat. No.: HY-P702716
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Species:
Source:
Cat. No.: HY-P705723
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Species:
Source:
Cat. No.: HY-P705725
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Species:
Source:
Cat. No.: HY-P705724
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: ABL1; BCR/ABL1 E1a2 Fusion Protein; Prev. ABL; BCR/C-ABL Oncogene Protein; JTK7; Chimeric BCR::ABL1 Protein; P150; BCR::ABL1 Fusion Protein; C-ABL; BCR/ABL E8a2 Fusion; V-ABL Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/ABL1 Fusion; C-ABL Oncogen
Species:
Source:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
